SYK Stock Price Today (October 2026) — Stryker Corporation Analysis & Key Metrics 2026-10-07
Stryker Corporation (SYK) is trading at $275.40, down 1.01% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $367.80 (33.6% upside).
- Volatility is low (20.30% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (9.40% YoY) alongside competitive pressures in the Medical Devices space.
SYK Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Stryker Corporation - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $117.61B
P/E Ratio
Forward P/E: 19.33
Revenue Growth
Year over Year
Analyst Target
+33.6% upside potential
Key Investor Questions About SYK
What investors need to know before buying
Based on current market data, SYK presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 43.68)
- Fundamentals say: Looking solid (debt and growth supportive)
SYK's growth trajectory depends on its ability to expand within the Medical Devices sector while managing margin pressures.
- Future growth will depend on performance in core Medical Devices operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for SYK investors include debt exposure and competitive dynamics in the Medical Devices industry.
- $15.45B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Medical Devices.
52-Week Trading Range
Over the past year, SYK stock traded between $267.00 and $392.55 and currently trades near the low end of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 20.30% annualized volatility and β=0.33, the stock exhibits low sensitivity to market moves—making SYK suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
What Does General Dynamics (GD) Winning New Stryker Work Mean Through 2028?
General Dynamics (NYSE:GD) received a new multi year U.S. Army contract modification for Double V Hull A1 Stryker vehicles, extending through 2028. The award enlarges the Army Stryker program backlog and adds funded production for upgraded armored vehicles across multiple brigade combat teams. The contract update supports continued manufacturing at General Dynamics Land Systems facilities that produce Stryker chassis and mission packages. The extra Double V Hull A1 Stryker work is...
Intuitive Surgical vs. Stryker: Which MedTech Stock Is the Better Buy Now?
ISRG's rapid procedure growth, expanding robotics ecosystem and recurring revenues highlight its growth path amid MedTech shifts.
Can Stryker Vehicle Demand Support General Dynamics' Growth?
GD's Stryker contract modification lifts cumulative value to $278.9M, supporting Land Systems demand through December 2028.
Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.
Stryker (SYK) Foot And Ankle Push Keeps Undervalued Narrative In Focus
Why Stryker’s new Foot & Ankle push matters for shareholders Stryker (SYK) is putting fresh attention on its Foot & Ankle franchise, rolling out new planning tools and limb reconstruction hardware at the 2026 AOFAS meeting in Seattle. The spotlight is on Prophecy Surgical Planning, now linked to the Incompass Total Ankle System, and on the Hoffmann LRF smartHEX platform, which extends the company’s reach into complex deformity correction supported by mobile software. Set against this product...
Stryker (SYK) Expanded Its Foot And Ankle Portfolio
Stryker (NYSE:SYK) announced new Foot & Ankle portfolio updates, including expanded Prophecy Surgical Planning, at a major industry meeting. The company introduced the Hoffmann LRF smartHEX system, aimed at limb reconstruction and patient connectivity in complex cases. Expanded planning tools and patient specific technologies are intended to support surgeon decision making in ankle replacement procedures. The Prophecy Surgical Planning expansion and Hoffmann LRF smartHEX launch sit alongside...
Stryker Facing Promising Setup Next Year, Trading Upside Limited in 2026, RBC Says
Stryker (SYK) will likely see an acceleration story in 2027, with high single digit growth achievabl
Stryker Expands Foot & Ankle Innovation With Prophecy and smartHEX
SYK expands its Foot & Ankle portfolio with Prophecy for Incompass and smartHEX, linking planning, implants and limb reconstruction.
GEHC or SYK: Which Is the Better Value Stock Right Now?
GEHC vs. SYK: Which Stock Is the Better Value Option?
Stryker (SYK) Stock Still Looks Cheap On Its 24% Slide
Stryker has seen its share price slide sharply over the past year, and the question now is whether the current valuation still lines up with the cash the business is expected to generate. For investors watching the stock after recent headlines, the focus has shifted from past returns to whether today's price fairly reflects those underlying cash flows. The stock has fallen 24.5% over the past year, which puts the spotlight on whether that move has brought the valuation closer to what its...
Explore More Analysis for SYK
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 29, 2026 (after the close)
Frequently Asked Questions
Common investor questions about Stryker Corporation
Stryker Corporation (SYK) is currently trading at $275.40. The RSI (14-day) is at 43.7, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $367.80 implies 33.6% upside from current levels. Volatility is moderate at 20.3% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Stryker Corporation (SYK): The trailing P/E ratio is 29.18, which is in line with broader market averages. The forward P/E is 19.33, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.52, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 4.51. Price-to-Sales is 4.18. Valuation should be compared to Medical Devices industry peers for context, as different sectors trade at different multiples.
Based on 25 analysts covering SYK, the consensus price target is $367.80. This represents a 33.6% upside from the current price of $275.40. The range spans from a low target of $298.00 to a high target of $465.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Stryker Corporation (SYK) pays a dividend with a current yield of approximately 1.28%. The annualized dividend rate is $3.48 per share. The payout ratio is 36.1%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was Sep 30, 2026.
Key risks for Stryker Corporation (SYK) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Medical Devices sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Stryker Corporation's (SYK) current debt and financial health profile: Total debt stands at $15.45B. The debt-to-equity ratio is 0.64x, which is moderate and generally manageable for most companies. The current ratio is 2.16, indicating strong short-term liquidity. The quick ratio is 1.08. The company holds $3.48B in cash and equivalents. Free cash flow is positive at $4.11B, providing a cushion for debt servicing and shareholder returns.